Curebase and AppliedVR partner to run clinical trials to assess the effectiveness of VR-based therapy

In Virtual Reality News

August 27, 2021 – Curebase, a company committed to democratizing access to clinical studies, and AppliedVR, a provider of virtual reality (VR) therapeutics and immersive treatments, have this week announced a one-year partnership where AppliedVR will deploy the Curebase platform to run five clinical trials assessing the effectiveness of VR-based therapy to treat chronic pain.

AppliedVR offers an evidence-based therapeutic VR platform for pain management, and has been used by more than 30,000 patients across more than 240 health systems globally, according to the company. The clinical trials with Curebase will focus on studying a self-administered, at-home VR therapy program, with Curebase software managing online patient recruitment, consent, participant engagement, and collecting patient reported outcomes. The Curebase platform will also support clinical workflows, including randomization schema, research coordinator communication, PI oversight, and coordination of VR headset and trial kit distribution.

“The Curebase approach enables AppliedVR to deliver a high-end patient experience for participants anywhere in the nation,” said Tom Lemberg, CEO and founder of Curebase. “For AppliedVR to commit to five studies over a one-year period, using the Curebase decentralized clinical trial platform, demonstrates how our technology and infrastructure provide the best virtual research solution in the industry. This further demonstrates how Curebase has uniquely met the needs of the growing digital therapeutic market to match innovation in digital medicines with equally innovative research solutions. Thanks to our established and unique approach, Applied VR will be empowered to recruit more quickly, experience improved trial compliance rates, and a more rapid research timeline.”

AppliedVR delivers VR-based treatments that address the complexity of chronic pain. Rooted in cognitive behavioral therapy and mindfulness, AppliedVR’s ‘EaseVRx’ solution includes a comprehensive approach that encompasses the biological, psychological and social factors that influence how people experience chronic pain.

In October last year, EaseVRx became one of the first VR-based therapeutics to receive its ‘Breakthrough Device Designation’ from the US Food and Drug Administration (FDA) for treating treatment-resistant fibromyalgia and chronic intractable lower back pain. Earlier this year, the company announced results from a trial which found that VR can be a holistic treatment for chronic pain. Moving forward, the Curebase platform will help AppliedVR study participants each day to comply with research protocols and report basic data about outcomes.

“Virtual reality holds tremendous potential to both improve and lower the cost of how we treat chronic pain while also reducing America’s dependence on pharmacological interventions. Demonstrating that requires effective clinical trials, and Curebase’s technology gives us a user-friendly, end-to-end solution that is highly workflow oriented and specialized for digital therapeutic study designs,” said Josh Sackman, President and co-founder of AppliedVR. 

For more information on AppliedVR and its therapeutic virtual reality solutions, please visit the company’s website.

Image credit: AppliedVR

About the author

Sam Sprigg

Sam is the Founder and Managing Editor of Auganix. With a background in research and report writing, he has been covering XR industry news for the past seven years.